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OBJECTIVE: To determine the impact of supplemental zinc, vitamin A, and glutamine alone or in combination
on growth, intestinal barrier function, stress and satiety-related hormones among Brazilian shantytown
children with low median height-for-age z-scores.
METHODS: A randomized, double-blind, placebo-controlled trial was conducted in children aged two months
to nine years from the urban shanty compound community of Fortaleza, Brazil. Demographic and
anthropometric information was assessed. The random treatment groups available for testing (a total of 120
children) were as follows: (1) glutamine alone, n= 38; (2) glutamine plus vitamin A plus zinc, n =37; and a
placebo (zinc plus vitamin A vehicle) plus glycine (isonitrogenous to glutamine) control treatment, n = 38.
Leptin, adiponectin, insulin-like growth factor (IGF-1), and plasma levels of cortisol were measured with
immune-enzymatic assays; urinary lactulose/mannitol and serum amino acids were measured with high-
performance liquid chromatography. ClinicalTrials.gov: NCT00133406.
RESULTS: Glutamine treatment significantly improved weight-for-height z-scores compared to the placebo-
glycine control treatment. Either glutamine alone or all nutrients combined prevented disruption of the
intestinal barrier function, as measured by the percentage of lactulose urinary excretion and the
lactulose:mannitol absorption ratio. Plasma leptin was negatively correlated with plasma glutamine
(p=0.002) and arginine (p=0.001) levels at baseline. After glutamine treatment, leptin was correlated with
weight-for-age (WAZ) and weight-for-height z-scores (WHZ) (p#0.002) at a 4-month follow-up. In addition,
glutamine and all combined nutrients (glutamine, vitamin A, and zinc) improved the intestinal barrier function
in these children.
CONCLUSION: Taken together, these findings reveal the benefits of glutamine alone or in combination with
other gut-trophic nutrients in growing children via interactions with leptin.
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& INTRODUCTION
Malnutrition is highly prevalent among children under
five years old in developing regions around the world (1).
Under-weight, defined by weight-for-age z-scores less than -
2 SD (reflecting acute malnutrition), affects 10% of these
children, which amounts to approximately 55 million
children worldwide (1). Stunting, defined by height-for-
age z-scores of less than -2 SD (reflecting chronic malnutri-
tion), affects 31% of these children, or approximately 170
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million (1). Wasting, defined by a weight-for-height-for-age
z score of less than -2 SD, affects 27% of children and is a
condition resulting from stunting, wasting, or both (2).
Childhood and maternal malnutrition are responsible for
21% of the global disability-adjusted life years (DALYs) and
2.2 million deaths annually (2).
The global extent of glutamine and arginine deficiency is
not well known, although one study has reported that even
nourished children or only mild-to-moderate undernour-
ished children often have low plasma concentrations of both
of these amino acids (3). Furthermore, deficiencies of
vitamin A and zinc are estimated to result in 0.6 and 0.4
million deaths, respectively, and account for a potential total
of 9% of global childhood DALYs (2,4).
Children with heavy enteric diseases and diarrheal burdens
early in life often suffer from life-threatening malnutrition and
growth retardation. Those children who survive to later
childhood or adulthood tend to have poor physical fitness
and reduced academic and work accomplishments, which are
associated with compromised cognitive development, and for
women, offspring with lower birth weights (5).
Hormone levels in growing children, such as leptin,
insulin-like growth factor-1 (IGF-1), adiponectin, and
cortisol, are affected by nutritional factors, daily diet, or
both during childhood. Leptin is produced primarily in the
adipose tissue and is positively associated with body
weight, body fat mass, and recent energy intake (6). In
non-obese persons, increased serum concentrations of leptin
are associated with decreased appetite (6). Adiponectin, like
leptin, is also produced by adipose tissue. However, in
contrast to leptin, serum concentrations of adiponectin are
lower in obesity and higher in individuals with lower body
fat mass (7). IGF-1 is an insulin-like hormone released by the
liver that reflects the hepatic anabolic-catabolic balance and
is increased by both caloric and protein intake (8). Thus,
IGF-1 is a useful biomarker for assessing nutritional status
(9). In contrast, cortisol levels are increased in malnutrition
(10). These hormones have interrelated effects on human
growth: leptin potentiates the action of IGF-1, whereas
glucocorticoids (such as cortisol) decrease IGF-1 expression,
interfere with IGF-1 signaling, and induce IGF-1 resistance
(11). In addition to their effects on human somatic growth,
these hormones may also affect immune responses.
Adiponectin and cortisol are associated with decreased
pro-inflammatory responses, whereas leptin and IGF-1 are
associated with an increased inflammatory state, which may
represent a compensatory adaptation to tissue recovery (12).
Nutrient tissue tropism, gut function, and growth have
critical relationships with variations in hormonal levels,
although these relationships have only recently emerged as
an important research area with potential relevance for
effective nutritional interventions (13).
Nutrients such as zinc and vitamin A potentially benefit
the catch-up growth following enteric infections and
diarrhea (14). In an animal study performed by our group,
zinc and glutamine improved behavior and growth in
undernourished mice during suckling (15). This improved
health status following intervention may be reflected by
increases in anabolic hormonal levels, such as IGF-1,
reflecting systemic improvements in physical growth and
fat mass. Zinc is known to increase serum levels of IGF-1
and leptin (16). Retinoids may increase IGF-1 synthesis in
the liver and aggravate the detrimental effects of corticos-
teroids on IGF-1 activity (17).
Glutamine, vitamin A, and zinc are known to enhance gut
barrier function by potentially improving nutrient absorption;
therefore, they may benefit growth development (3,18). In
fact, our group showed that oral administration of a
glutamine derivative, alanyl-glutamine, improved both the
intestinal barrier and weight gain in children living in
an urban community in Fortaleza, CE, Brazil (3). Thus, we
hypothesized that glutamine supplementation alone or in
combination with vitamin A and zinc would have a positive
impact on the intestinal barrier function and consequently
trigger growth improvements in young children (3). These
associations would be positively correlated with increased
plasma leptin and IGF-1 levels and negatively correlated with
cortisol and adiponectin. In addition, we investigated whether
the combination of glutamine with zinc and vitamin A (two
critical gut-trophic nutrients) would additively improve the
aforementioned parameters compared with glutamine alone.
& MATERIALS AND METHODS
Ethics
The study was approved by the Institutional Review
Boards (IRBs) of the Federal University of Ceara´ (UFC),
Fortaleza, Ceara´, Brazil, and the University of Virginia.
Informed consent was obtained from all participants.
Environment and population
The study population is located in the Parque Universita´rio
community (3 4˚4’58.27’’ south and 38 3˚4’30.80’’ west) in
Fortaleza, Ceara´, northeast Brazil, which is 5 km distant from
the Clinical Research Unit and Institute of Biomedicine/
Center for Global Health (www.upcibimed.ufc.br) labora-
tories in Fortaleza. Fortaleza has an estimated population of
2.6 million inhabitants and an infant mortality rate of
35 deaths per 1,000 live births. A 1998 census of Parque
Universita´rio revealed a total population of 3,541 inhabitants,
of which 957 (27%) were children under the age of 9. The
children in this study were a subset of a larger cohort residing
in historically endemic settings of enteric and diarrheal
illnesses and were thereafter enrolled in a randomized,
double-blind, community-based trial to examine the effects of
glutamine, vitamin A, and zinc on intestinal barrier function
and physical growth. Children aged three months to nine
years were initially identified by a community census and
screened for height or length measurements. Children were
selected if they met the following inclusion criteria: (a) height
(or length)-for-age z-scores (HAZ) less than the median for
this population (-0.06 z-score), (b) community residency, and
(c) parental or guardian consent. The exclusion criteria were
as follows: (a) no sibling enrolled in this or any other study in
the last two years, (b) a fever.38 C˚ at time of enrollment, and
(c) a recognizable chronic condition affecting growth, such as
celiac disease, tuberculosis, or any clinically identifiable
chronic disease. Figure 1 shows a chart of the subjects
enrolled in the study protocol. The treatment protocol is
summarized in Table 1.
Study design
This study is a prospective, double-blind, randomized,
placebo-controlled trial and is registered as a clinical trial
(NCT00133406) at the US National Library of Medicine
(http://www.clinicaltrials.gov). Enrollment/recruitment
was conducted from June 2000 until August 2004. After
parental consent was obtained, an experienced field study
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team (1 nurse and 2 community health workers) inter-
viewed parents and children to collect demographic
information, including age, gender, birth weight, level of
maternal education, family income, and baseline anthropo-
metric information. A consultant statistician assessed the
study design and power. The participants and the study
team were blinded to the intervention assignment.
Demographic and anthropometric data, information on
adverse events and serious adverse events, and laboratory
data were collected in case report forms at the field area and
at laboratories located at the INCT-Biomedicine, UFC. The
adverse event and serious adverse event recording and
reporting system were developed and monitored by the
National Institutes of Health (NIH), the National Institute of
Allergy and Infectious Diseases (NIAID), and the Division
of Microbiology and Infectious Diseases (DMID).
Nutritional intervention and surveillance
A total of 314 children were randomized with respect to
receiving vitamin A (100,000 IU retinyl palmitate if ,12
months old or 200,000 IU retinyl palmitate if $12 months
old every four months), which was given in one dose at 0, 4,
and 8 months into the study protocol; zinc, which was given
twice weekly at a dose of 40 mg; or both vitamin A and zinc.
The study was conducted for 1 year, and half of each group
received glutamine (16-g daily dose given over ten days
Figure 1 - Flow of micronutrient supplementation and biochemistry blood testing to study growth, intestinal barrier function, stress
and satiety related hormones in Brazilian shantytown children from Fortaleza, northeastern, Brazil, during June 2000 - August 2004,
with follow-up between June 2000 and December 2007.
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starting at the first month of the study protocol) (22). A total
of 167 children were available and eligible for cognitive
testing. Trained health care agents working on the study
surveillance team administered the micronutrients. The
health care workers administered the micronutrients during
home visits with direct observation of intake.
L-Glutamine was obtained from Rexim (Courbevoie,
France); L-glycine and zinc acetate were obtained from
Spectrum Chemicals (Gardena, CA, USA); vitamin A
(retinyl palmitate in vegetable oil with 40 IU of alpha-
tocopherol as an antioxidant) was obtained from Hoffman-
La Roche, Basel, Switzerland. Isomolar glycine (8.3 g/daily)
was used as a placebo for glutamine, Tanjal juice was used
as a placebo for zinc, and the same amounts of alpha-
tocopherol and vegetable oil were used as a placebo for
vitamin A. Tocopherol was chosen as a placebo for vitamin
A because it is also a fat-soluble vitamin and the tocopherol
dosing preparation is similar to that of vitamin A (capsule
dosing). The color, size, and taste were the same between
vitamin A and placebo capsules.
A computer-generated random number list was used to
assign children to one of eight treatment arms: 1) Placebo; 2)
Glutamine; 3) Zinc; 4) Vitamin A; 5) Glutamine + Zinc; 6)
Glutamine + Vitamin A; 7) Zinc + Vitamin A; or 8) Glutamine
+ Zinc + Vitamin A. The treatment group and the oral
treatment regimen, including dose, frequency, and duration
of supplementation, are outlined in Table 1. A member of the
field study team who was blinded to the treatment group
administered the supplements and visited each child twice
weekly to assess tolerance and any adverse effects of
supplementation. No significant differences in the rate of
adverse events were identified between the treatment groups.
Biochemical analyses
Blood samples were collected from fasted subjects at 0
and 4 months, and the samples were stored at -80 C˚ until
analysis. Glutamine and arginine were measured as
reported elsewhere (19). Leptin, adiponectin, IGF-1, and
cortisol levels were measured in plasma samples using an
enzyme-linked immunosorbent assay according to the
manufacturer’s instructions (R&D Systems, Minneapolis,
MN).
Anthropometric measurements
Anthropometric measurements were obtained at 0, 4, and
8 months. A calibrated digital weight scale with 100 g
precision (Tanita Solar Scale, Tanita Corporation of America
Inc., Arlington, IL) was used to weigh each child. All
measurements were performed using standard methods, as
described elsewhere (3). Weights were measured with a
calibrated digital weighing scale with 100 g precision
(Tanita Solar Scale, Tanita Corporation of American Inc.,
Arlington, IL). Height was measured in the supine position
for children under 24 months old and standing for children
aged 24 months or older using an anthropometric rod with
an accuracy of 0.1 cm. As markers of physical development
and nutritional status, HAZ, weight-for-age z-scores (WAZ),
and weight-for-height z-scores (WHZ) were calculated
using the anthropometric software Epi-Info (Centers for
Disease Control, Atlanta, GA, USA). These anthropometric
z-scores represent the number of standard deviations above
or below the median values for the National Center for
Health Statistics (NCHS) and the International Reference
Population (21).
Intestinal permeability assay
The intestinal permeability assay was performed at 0 and
4 months, as described in the protocol (Figure 1). The
children were fasted for at least 3 hours prior to ingesting
20 mL of a solution containing lactulose (250 mg/mL;
Lactulona, Luitpold Produtos Farmaceˆuticos Ltda.,
Barueri, Sa˜o Paulo, SP) and mannitol (50 mg/mL;
Table 1 - Characteristics of children at baseline, including age, sex, anthropometric indices, intestinal permeability, and
treatment group.
Parameters
Controla
(n = 38)
Glutamineb
(n= 38)
Glutamine + Vitamin A + Zincc
(n = 37)
Total
(n = 113)
Age
(months; median and range)
47 (6.77-98.75) 40 (7.65-104.76) 48 (4.86-99.01) 45 (4.86-104.76)
Sex (male; n [%]) 20 (53) 19 (50) 20 (54) 59 (52)
Z-Score (mean¡sem)
Weight-for-age -0.985¡0.1856 -0.500¡0.1401 -0.671¡0.1786 -0.719¡0.0993
Height-for-age -1.158¡0.1482 -0.654¡0.1401 -0.925¡0.1626 -0.913¡0.0889
Weight-for-height -0.187¡0.2371 -0.025¡0.1291 -0.024¡0.2008 -0.080¡0.1124
Lactulose:mannitol ratio
(median and range)
0.081
0.005-1.125
0.065
0.001-1.390
0.130
0.016-1.123
0.083
0.001-1.390
Adiponectin (ng/ml)
(median and range)
9.401
8.268-10.233
9.370
7.920-10.419
9.834
8.948-10.807
9.586
7.920-10.807
Cortisol (ng/ml)
(median and range)
2.800
1.429-3.726
2.838
1.346-4.196
2.986
2.049-3.843
2.870
1.346-4.196
IGF-1 (ng/ml)
(median and range)
3.346
2.293-5.078
3.396
2.240-5.474
3.683
1.892-4.718
3.574
1.892-5.474
Leptin (pg/ml) 7.242
6.692-8.375
6.882
5.895-9.333
6.940
6.175-9.205
7.001
5.895-9.333
There were no significant differences between the control group and the treatment groups (p.0.05).
The intervention protocol was performed as follows:
aControl group= tocopherol (40 IU) at 0 and 4 months; zinc vehicle (tangerine juice) twice a week for four months; and isomolar glycine (8.3 g/day for ten
days starting at month one of the study protocol).
bGlutamine group=16.2 g/day for ten days starting at month one of the study protocol.
cGlutamine plus vitamin A plus zinc group=glutamine following the dose and schedule described above; vitamin A (retinyl palmitate, 100,000 IU for
children , 12 months old or 200,000 IU for children $12 months old) at 0 and 4 months; and zinc acetate 40 mg twice a week for four months.
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HenriFarma Produtos Quı´micos e Farmaceˆuticos Ltda., Sa˜o
Paulo, SP). Urine samples were collected after lactulose and
mannitol ingestion and were stored at -80 C˚ until analysis.
Sample size and statistical analyses
Based on previously published data (3), a sample size of
35 for each group was chosen with an effect of 0.36 SD with
80% power (2-tailed test with a type I error of 5%) in the
mean WHZ, WAZ, and HAZ changes among children
receiving glutamine, glutamine plus zinc and vitamin A, or
the placebo-glycine control group, with an estimate of 15%
loss to follow-up. For the secondary parameter, the
lactulose:mannitol ratio (pilot data: mean 0.13¡0.04 SD),
an estimated sample size of at least 35 subjects for each
treatment group was calculated for the intervention study,
assuming a 30% loss to follow-up (p,0.05, power: 80%). To
assess treatment-related differences in the plasma concen-
trations of leptin, adiponectin, IGF-1, and cortisol, we
determined an effect size of 0.7 SD with these group-wise
comparisons and two-sided statistical analyses, and a
sample size of approximately 41 subjects per treatment
group was estimated (p,0.05, power: 80%).
The data were entered twice and were validated by three
independent personnel using Access software (Microsoft
Corporation, New York, NY). Epi Info Nutstat software
(version 6.0; Centers for Disease Control and Prevention,
Atlanta, GA) was used to calculate the nutritional para-
meters. Parametric (Student’s t tests) and non-parametric
(Mann-Whitney test) tests, along with the chi-square test or
Fisher’s exact test for categorical variables, were used as
indicated to compare differences between the treatment
groups. Either Pearson (product-moment correlation) or
Spearman (two continuous variables) correlations were
used to assess associations between plasma hormone levels
and anthropometrics. An analysis of covariance was used to
examine associations between hormone concentrations and
anthropometric parameters. All statistical analyses were
performed using the Statistical Package for Social Sciences,
version 11.5 (SPSS Inc., Chicago, IL). P-values of 0.05 or less
were accepted as statistically significant. GraphPad Prism
version 3.0 (GraphPad Software, San Diego, CA) was used
for figures and tables.
& RESULTS
The children had an overall median age of 37 months at
the study onset (range: 4.9 to 109.6 months), and the control
and treatment groups were not significantly different at
baseline with respect to age, sex, anthropometry, or
lactulose:mannitol ratio (Table 1).
The plasma concentrations of hormones at baseline were
as follows (median and range): leptin = 7.0 (5.89-9.33) pg/
mL; IGF = 3.57 (1.89-5.47) ng/mL; adiponectin = 9.58 (7.92-
10.8) ng/mL; cortisol = 2.87 (1.34-4.19) ng/mL (Table 1).
Leptin and IGF-1 were positively correlated with age,
height, and weight in these children at baseline (Table 2).
Adiponectin and cortisol decreased with increasing age,
height, and weight (Table 2). Only adiponectin had a
significant positive correlation with HAZ. None of the
intestinal barrier function parameters, such as percentage of
mannitol and lactulose urinary excretion and the lactulo-
se:mannitol ratio were significantly correlated with leptin,
IGF-1, adiponectin, or cortisol (Table 2). The leptin/
adiponectin ratio was positively correlated with age
(Spearman’s correlation; n = 91; r = 0.32; p = 0.0018). Z-scores
for WAZ, HAZ, and WHZ or intestinal barrier function
parameters were not significantly correlated with the
leptin/adiponectin ratio (Spearman’s correlation; p.0.05).
Only leptin had significant positive correlations with IGF-1
at baseline, and the leptin/adiponectin ratio was also
positively correlated with IGF-1 and was significantly
negatively correlated with cortisol (Table 2).
Figure 2 shows the cumulative changes (final minus
initial measurement for the eight-month follow-up). The
cumulative changes in WHZ (adjusted for age) over
the eight-month follow-up period revealed a significant
increase in the glutamine group compared with the placebo
group (0.26¡0.02 vs. -0.08¡0.01; p= 0.03); however, the
changes in WAZ and HAZ were not significant (data not
shown). The combination of glutamine with zinc and
vitamin A improved growth; however, the improvement
was not significant when compared to the placebo-glycine
group (0.096¡0.05; p= 0.277).
Glutamine treatment significantly reduced the percentage
of lactulose (median: 0.16 and range: 0.02-3.08 vs. median:
0.52 and range: 0.01-25.17; p= 0.008) and the urinary
mannitol excretion (2.99 and 0.05-24.07 vs. 6.89 and 0.17-
35.5; p= 0.0038) compared with the placebo-glycine group.
All of the nutrients combined also significantly decreased
the lactulose:mannitol ratio compared with the glutamine-
treated group (0.079 and 0.009-0.52 vs. 4.73 and 0.27-45.83;
p= 0.041). The lactulose:mannitol scores were not signifi-
cantly correlated with the hormone levels assessed before or
after treatment with glutamine or in combination with
vitamin A and zinc.
A total of 27 children (27/104; 26%) experienced adverse
events, and 13 children (13/104; 12.5%) had serious adverse
events. The rates of adverse and serious adverse events
were similar in all study groups (p.0.05). The most
common serious adverse events were respiratory infections
(n = 4), pneumonia (n = 2), asthma complications (n = 6), and
diarrhea (n = 1). There were no deaths.
Treatment with glutamine alone or all nutrients combined
did not significantly affect the selected plasma hormone
levels at four months of evaluation (p,0.05). Differences
identified between the treatment groups were also not
altered by glutamine alone or glutamine combined with
vitamin A and zinc. We examined the plasma glutamine
and arginine concentrations at baseline with respect to the
hormone concentrations and noted a significant positive
correlation between glutamine and arginine concentrations
(Pearson correlation; n = 62, r = 0.83, p,0.0001) and signifi-
cant negative correlations between leptin and both gluta-
mine and arginine (n = 56; leptin vs. glutamine, r = -0.27,
p= 0.042; leptin vs. arginine, r= -0.35, p= 0.007) (Figure 3).
The significant negative correlations between leptin and
both glutamine and arginine were abolished by 4 months of
treatment with glutamine (n = 19; leptin vs. glutamine, r =
-0.15, p= 0.51; leptin vs. arginine, r = -0.423, p = 0.071).
Using Spearman’s correlation analyses, we found that
plasma leptin levels were significantly positively correlated
with WHZ; however, plasma leptin levels were negatively
correlated with increases in WAZ and WHZ between 0 and
4 months in the control group. Treatment with glutamine
alone or in combination with vitamin A and zinc abolished
the negative correlation between leptin and changes in
WAZ and WHZ (delta scores), and both glutamine treat-
ment groups exhibited significantly improved correlations
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between the leptin or the leptin/adiponectin ratio and
WAZ/WHZ. The percentage of lactulose excretion and the
lactulose:mannitol ratio were also significantly associated
with leptin plasma levels in the control group at four
months; however, treatment with glutamine alone or in
combination with vitamin A and zinc did not show this
association. Controls and subjects treated with glutamine
alone or in combination with vitamin A and zinc continued
to demonstrate positive correlations between IGF-1 plasma
concentrations and age, height, and weight at four months.
A negative correlation was observed at four months
between IGF-1 and delta-HAZ, although there was a
significant positive correlation between IGF-1 delta-WHZ.
Treatment with glutamine alone abolished the negative
correlation between adiponectin plasma concentrations and
age. Because leptin levels were associated with growth
parameters and leptin was associated with glutamine alone
or in combination with vitamin A and zinc, we further
analyzed leptin concentrations at four months (i.e., after
treatment), controlling for paired initial leptin concentra-
tions (at time 0), gender, and WAZ at time 0. Table 3
summarizes these analyses. Among the subjects treated
with glutamine alone or in combination with vitamin A and
zinc, leptin plasma levels were significantly correlated with
WAZ and WHZ, even after controlling for gender and the
leptin plasma level at baseline.
& DISCUSSION
This double-blinded, controlled clinical trial enrolled
children at risk for enteric infections and diarrhea and
demonstrated that glutamine treatment significantly
enhanced physical growth, as determined by improvements
in cumulative WHZ, compared to the placebo-glycine
group. The positive effect of glutamine on growth was
consistent with our previous report showing that treatment
with alanyl-glutamine (a glutamine-derivative dipeptide)
improved child growth rates after a four-month follow-up
compared to placebo controls in the same setting (3).
Additionally, the benefit of this nutrient on the intestinal
barrier function was shown by decreased lactulose epithelial
permeation (i.e., reduced urinary excretion) in the lactulo-
se:mannitol assay, which is an indicator of a more intact
intestinal epithelial barrier.
Our data indicated that leptin and IGF-1 were positively
correlated with age, height, and weight in these children at
baseline, whereas adiponectin and cortisol plasma levels
decreased with increasing age, height, and weight. Thus,
these hormone levels may provide a marker not only for
obesity and metabolic syndrome but also for nutritional
status in children, especially during catch-up growth in
children with lower HAZ (lower than the median z-score of
the study population). In addition, the catch-up growth after
diarrheal illnesses and the growth and satiety-related
hormone levels may be strongly influenced by a genetic
component (20,21).
In addition, our findings indicate that plasma leptin and
the leptin/adiponectin ratio had a significant positive
correlation with IGF-1; however, the leptin/adiponectin
ratio had a significant negative correlation with cortisol.
Leptin was originally suggested as an ‘‘anti-obesity’’
hormone because of its suppressive effects on appetite,
which was further supported by animal studies. However,
the relationships between ob/ob leptin tissue receptors and
leptin signaling proved to be far more complex, as treatment
of obese individuals with leptin mostly failed to promote
weight loss due to increased tissue resistance to leptin
(22,23).
Table 2 - Spearman correlation coefficients for leptin, IGF-1, adiponectin, and cortisol plasma levels vs. age,
anthropometric measures, and intestinal barrier function parameters in young children.
Parameters Leptin IGF-1 Adiponectin Cortisol
n r p n r p n r p n r p
Age (month) 91 0.205 0.051 90 0.457 0.000 91 -0.246 0.019 90 -0.223 0.034
Height-for-age 91 0.002 0.987 90 0.183 0.084 91 0.235 0.025 90 -0.078 0.465
Weight-for-age 91 0.045 0.670 90 0.018 0.869 91 0.017 0.875 90 -0.050 0.639
Weight-for-height 89 0.046 0.669 88 -0.168 0.117 89 -0.064 0.553 88 0.044 0.686
% Mannitol 89 0.067 0.532 88 0.151 0.160 89 -0.123 0.251 88 -0.182 0.089
% Lactulose 79 0.216 0.056 78 0.066 0.566 79 0.066 0.562 78 -0.066 0.567
Lact./mannitol ratio 79 0.083 0.467 78 -0.092 0.423 79 0.160 0.159 78 0.087 0.451
Leptin 91 - - 90 0.522 0.000 90 -0.014 0.896 91 0.137 0.195
IGF-1 90 - - - - - 89 -0.024 0.822 90 0.069 0.518
Adiponectin 91 - - - - - - - - 90 0.55 0.604
Leptin/Adiponectin 91 0.761 0.000 90 0.392 0.000 90 -0.068 0.522 91 -0.474 0.000
n=number of children; r= Spearman correlation coefficient; p= statistical significance value.
Figure 2 - Cumulative weight-for-height z-score (WHZ) with
adjustment for age and season over eight months follow-up in
Brazilian shantytown children from Fortaleza, northeastern,
Brazil, treated with placebo, glutamine (Gln), and glutamine
plus zinc (Zn) and vitamin A (VitA).
Glutamine, growth, and hormonal testing
Lima AA et al.
CLINICS 2014;69(4):225-233
230
Recently, serum leptin levels have been associated with
increased body mass index in both children and adults (24).
In undernourished children at baseline, plasma leptin levels
have been positively correlated with IGF-1 levels and
negatively correlated with cortisol levels (10,25). IGF-1, the
growth hormone mediator, may function in concert with
leptin to enhance childhood somatic growth (10,25).
Adiponectin serum levels have been found to be consis-
tently negatively correlated with body fat mass (26).
However, in this study, adiponectin, leptin, IGF-1, and
cortisol plasma concentrations were not significantly asso-
ciated with body weight.
Glutamine and arginine levels in undernourished chil-
dren have not been well documented. In the current study,
the concentrations of these two amino acids were lower than
the normal range observed in healthy children (glutamine:
0.479-0.821 mmol/mL; arginine: 0.120-0.144 mmol/mL) (3). In
addition, glutamine and arginine plasma levels showed
consistent and significant positive correlations with each
other, suggesting that these important amino acids syner-
gistically interact to exert beneficial effects on child growth
and development. However, the mechanisms underlying
these interactions remain unclear. Recently, glutamine has
been associated with improved intestinal barrier function
and improved child growth and development in various
pre-clinical and clinical studies (3,4). Both glutamine and
arginine stimulate immune responses and intestinal cell
proliferation and migration through protein kinase-depen-
dent pathways, and they appear to have an additive effect
on these cells (27,28). Plasma leptin concentrations were
significantly negatively correlated with plasma glutamine
and arginine levels at baseline in this study. These results
suggest that leptin co-regulates amino acid uptake in target
cells, which might have implications for childhood growth.
As shown in this work, treatment with glutamine comple-
tely abolished the negative correlation of leptin with these
two plasma amino acids, suggesting that these amino acids
downregulate leptin secretion and may stimulate fat
deposition.
Leptin and IGF-1 showed significant positive correlations
with age, and adiponectin and cortisol showed significant
negative correlations with age. Previous studies have also
shown that leptin and IGF-1 levels increase with age, while
adiponectin and cortisol levels decrease with age (11).
During puberty, leptin levels increase dramatically, whereas
adiponectin levels decrease (29,30). Our findings revealed a
similar pattern with respect to these hormones and weight/
height. Thus, leptin and IGF-1 were significantly positively
correlated with weight and height, whereas adiponectin and
cortisol were significantly negatively correlated with weight
and height. A recent work also reported a positive
correlation of leptin and IGF-1 with body mass index and
height-for-age in normally nourished children and a
positive correlation of plasma IGF-1 with mid-arm circum-
ference and height-for-age score in malnourished children
(25). Researchers consistently agree that plasma leptin levels
in children and adults are associated with body mass index,
fat mass, insulin resistance, and dyslipidemia (24).
However, adequate concentrations of leptin are necessary
for immune competence because this hormone enhances
thymic growth, lymphocyte proliferation, and macrophage
pro-inflammatory response (31). Conversely, although
adiponectin may have beneficial cardiovascular effects,
excessive levels, as observed in malnutrition, may be
immunosuppressive (32).
Neither glutamine alone nor glutamine given with zinc
and vitamin A altered plasma concentrations of leptin,
Figure 3 - Correlation at baseline between leptin, plasma
glutamine and arginine concentrations on control, glutamine
alone or all nutrients combined. A. Correlation of plasma
glutamine with arginine concentration. B. Correlation of leptin
with glutamine concentration. C. Correlation of leptin with
arginine concentrations.
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adiponectin, IGF-1, and cortisol. However, this study
suggested that glutamine or all nutrients combined function
in the co-regulation of leptin to improve WAZ and WHZ
even after controlling for initial plasma leptin concentration
and gender. Neither glutamine alone nor glutamine
combined with zinc and vitamin A significantly altered
the correlations of IGF-1, adiponectin, and cortisol with
anthropometric measurements. One study examined the
effect of zinc on leptin and ghrelin plasma concentrations
and showed that this nutrient did not alter the concentra-
tions of these hormones either during or after treatment;
however, zinc improved the positive correlation between
leptin and weight-for-age z-scores over a three-month
period (13). Buyukgebiz and colleagues also reported that
leptin was increased only in children who exhibited catch-
up growth, and the increases in leptin levels were much
higher in children with protein-energy malnutrition com-
pared with healthy control children (33). The lack of an
effect of these nutrients on plasma leptin concentrations
does not rule out a possible influence on the leptin axis
because the effect could be mediated via an excess of soluble
plasma leptin receptor. Stein and colleagues showed that in
severely malnourished children receiving nutritional sup-
port, leptin and the molar excess of soluble leptin receptor
divided by the leptin concentration are better biomarkers of
nutritional status than IGF-1 during nutritional recovery
(34). Because we did not measure the soluble leptin
receptor, our analysis was limited to the leptin plasma
concentration. These results suggest that glutamine given
alone improves child growth as measured by the change in
WHZ and that this effect partially correlated with increasing
plasma leptin levels. An intestinal repair effect was
observed with glutamine and glutamine plus vitamin A
and zinc, based on the percentage of lactulose excretion and
the lactulose:mannitol ratio, respectively; however, the
intestinal barrier function was not significantly correlated
with these plasma hormones. Moore and colleagues also
found that plasma leptin levels had no detectable relation-
ship with the intestinal barrier function in moderately
malnourished rural Gambian children (35).
The intriguing finding of a negative correlation of plasma
glutamine and leptin levels at baseline may be explained by
a preexisting chronic inflammatory state of the study
children, that inflammatory state could have increased
blood C-reactive protein levels that may have impaired
the leptin binding to leptin receptors and therefore increas-
ing its circulating levels (36). The same chronic inflamma-
tory state may have caused a decline in plasma glutamine
levels, altogether these effects would have been ameliorated
with glutamine supplementation.
We acknowledge that the study population shows some
age heterogeneity, which could create some bias in the
study analyses, although age and seasonality were con-
trolled for in the analysis. There were totals of thirteen, ten,
and ten children below two years old in the placebo,
glutamine-treated, and three-nutrient-treated (glutamine,
zinc, and vitamin A) groups, respectively. The covariance
analyses of growth between these groups were performed
with adjustments for age and season (dry and rainy seasons
in Fortaleza); thus, the possible influences of these factors
were taken into consideration. We also performed indepen-
dent t test analyses, and we did not identify significant
differences between groups after splitting the groups into
,2 years old and $2 years old. Another limitation was that
HAZ (i.e., LAZ = length-per-age z-score for infants) might
not be the best criterion for studying growth parameters
in infants; however, HAZ has been indicated as a good
surrogate measure of long-term growth deficits following
enteric infections and diarrhea (4). To avoid the influence of
any significant differences in the baseline data between
groups, we used delta values (final minus initial value) for
all observed growth parameters.
In conclusion, these results suggest that glutamine
treatment improved growth as measured by the cumulative
WHZ, possibly via interactions with leptin, as suggested by
positive correlations with this satiety-related hormone.
However, IGF-1, adiponectin, and cortisol were not corre-
lated with increased WAZ and WHZ in this population. In
addition, glutamine alone or all nutrients in combination
(glutamine, vitamin A and zinc) improved the intestinal
Table 3 - Pearson correlations illustrating the relationship between plasma leptin concentrations, weight-for-age
(WAZ), weight-for-height (WHZ), and change (0-4 months) in WAZ and WHZ in the placebo-glycine control and the
glutamine treatment group (alone or in combination).
Ln (Leptin) t = 4 Ln (Leptin) t = 4 Ln (Leptin) t = 4
Treatment Group Variable Controlling for ln_Leptin t = 0
Controlling for ln_Leptin t = 0 and
sex Controlling for WAZ t = 0
Time (4 months) n r p n r p n r p
Control WAZ 27 0.192 0.347 27 0.189 0.365 29 0.010 0.958
WHZ 27 0.384 0.053 27 0.366 0.072 - - -
Delta WAZ 27 -0.346 0.083 27 -0.332 0.105 29 -0.010 0.958
Delta WHZ 27 -0.400 0.043 27 -0.397 0.050 - - -
Glutamine WAZ 25 0.524 0.009 25 0.525 0.010 30 0.244 0.202
WHZ 23 0.702 0.000 23 0.774 0.000 - - -
Delta WAZ 25 0.185 0.387 25 0.165 0.453 30 0.244 0.202
Delta WHZ 23 0.407 0.060 23 0.393 0.078 - - -
Glutamine plus WAZ 28 0.451 0.018 28 0.446 0.022 28 0.095 0.639
Vitamin A and WHZ 27 0.500 0.009 27 0.510 0.009 - - -
Zinc Delta WAZ 28 0.304 0.123 28 0.332 0.097 28 0.095 0.639
Delta WHZ 27 0.107 0.602 27 0.112 0.594 - - -
n=number of children; r=Pearson correlation coefficient; p= statistical significance value.
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barrier function, which likely contributed to the growth
benefits observed in these children.
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